




## STATE MEDICAID P&T COMMITTEE MEETING

Thursday, March 20, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 114



# MINUTES

### Committee Members Present:

Lisa Hunt, R.Ph.

Ellie Brownstein, M.D.

Julia Ozbolt, M.D.

Beth Johnson, R.Ph.

Roger Martenau, M.D.

### Committee Members Excused:

Kort Delost, R.Ph.

Elizabeth Young, Pharm.D.

Jameson Rice, Pharm.D.

Bernadette Kiraly, M.D.

### Dept. of Health/Div. of Health Care Financing Staff Present:

Trevor Smith, Pharm.D.

Robyn Seely, Pharm.D.

Richard Sorenson, RN

### University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Gary Oderda, UofU

### Other Individuals Present:

Lori Harwarth, Bayer

Camille Kerr, Allergan

Greg Larson, Gilead

Paul Bonham, NovoNordisk

Chad Burnham, Select Health

Kim Eggert, Gilead

Meeting conducted by: Lisa Hunt

---

1. **Review and Approval of March Minutes:** Kort Delost was excused for the March meeting. Lisa Hunt conducted this meeting. Julia Ozbolt made a motion to approve February minutes; Ellie Brownstein seconded the motion, all in favor.
2. **Housekeeping:** The 2014 PDL is now live on, and is posted on the Utah Medicaid website.
3. **Drug Utilization Review (DUR) Board update:** Robyn Seely reported that the March DUR Board discussed new Hepatitis C agents, Olysio and Sovaldi. April meeting will be on Daliresp for COPD indications.
4. **Antiemetic Agents:** Melissa Archer presented a review of antiemetics agents. Seven agents were presented for review, however scopolamine was not listed on the agenda so it was not included for review in the March meeting. This agent will be presented in the April P&T meeting. Peer-reviewed research regarding the safety and efficacy of each

agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

5. **Other States Report:** Lisa Hunt presented the PDL status of these drugs from other States.

6. **No Public comment**

7. **Committee discussion**

- a. Melissa Archer reported that ondansetron was not included as it is already included in the PDL.
- b. A question was posed about if trimethobenzamide is still available. Robyn Seely reported that the drug is not on the FDA shortage list.
- c. Melissa Archer said that she believes the promethazine cough syrups were included in the utilization data presented.
- d. Beth Johnson asked about black box warnings that any of these agents may have. She said that injectable promethazine and prochlorperazine are the agents that concern her with potential safety issues.
- e. Beth Johnson asked about putting an age restriction on the promethazine for children under age two. The DUR Board is charged with making the decisions on age and criteria limits on specific drugs.
- f. Beth Johnson made a motion to request that the DUR board look at antiemetic agents with black box warnings for potential criteria or age restrictions. Julia Ozbolt seconded the motion, all in favor.
- g. Julia Ozbolt made a motion that all agents are equally safe and effective for inclusion on the PDL except for the injectable promethazine. Roger Martenau seconded the motion, all in favor.

8. **Appetite Stimulant Agents:** Melissa Archer presented a review of appetite stimulant agents. Three agents were presented for review. Peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

9. **Other States Report:** Lisa Hunt presented the PDL status of these drugs from other States.

10. **No Public comment**

11. **Committee discussion**

- a. One agent, Oxandrin, is already on the PDL under the androgenic agents, so it requires a clinical prior authorization.
- b. Beth Johnson said that she doesn't see major safety or efficacy differences between the agents. She said that there doesn't appear to be very much usage in these agents.
- c. Beth Johnson asked what the criteria is for Oxandrin. It was reported that it requires criteria for androgen treatment.

- d. A question was made about putting the Oxandrin in both the Androgen class and the Appetite stimulant class. Lisa Hunt said that putting an agent in two classes has been done before, and is allowed in some cases.
  - e. Beth Johnson made a motion to include the other 2 appetite stimulant agents on the PDL. Julia Ozbolt seconded the motion. All in favor.
  - f. Beth Johnson recommended that the DUR board make criteria on Oxandrin for patients needing an appetite stimulant
12. Next meeting is scheduled for April 17, 2014. Scopolamine agents, Epinephrine pen formulation agents and the annual public meeting training will be the topics discussed.

---

Minutes prepared by Trevor Smith

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)